The oncogenic role of hepatitis delta virus in hepatocellular carcinoma
Summary: Hepatitis delta virus (HDV) is a small defective virus that needs hepatitis B virus (HBV) to replicate and propagate. HDV infection affects 20-40 million people worldwide and pegylated interferon (PegIFN) is the only recommended therapy. There is limited data on the contribution of HDV infe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-08-01
|
| Series: | JHEP Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555919300345 |
| _version_ | 1828311972065574912 |
|---|---|
| author | Marc Puigvehí Carlos Moctezuma-Velázquez Augusto Villanueva Josep M. Llovet |
| author_facet | Marc Puigvehí Carlos Moctezuma-Velázquez Augusto Villanueva Josep M. Llovet |
| author_sort | Marc Puigvehí |
| collection | DOAJ |
| description | Summary: Hepatitis delta virus (HDV) is a small defective virus that needs hepatitis B virus (HBV) to replicate and propagate. HDV infection affects 20-40 million people worldwide and pegylated interferon (PegIFN) is the only recommended therapy. There is limited data on the contribution of HDV infection to HBV-related liver disease or liver cancer. Evidence from retrospective and cohort studies suggests that HBV/HDV coinfection accelerates progression to cirrhosis and is associated with an increased risk of hepatocellular carcinoma (HCC) development compared to HBV monoinfection. Although the life cycle of HDV is relatively well known, there is only ancillary information on the molecular mechanisms that can drive specific HDV-related oncogenesis. No thorough reports on the specific landscape of mutations or molecular classes of HDV-related HCC have been published. This information could be critical to better understand the uniqueness, if any, of HDV-related HCC and help identify novel targetable mutations. Herein, we review the evidence supporting an oncogenic role of HDV, the main reported mechanisms of HDV involvement and their impact on HCC development. Keywords: Hepatitis B virus, liver cancer, HCC, co-infection, molecular pathogenesis, defective, superinfection |
| first_indexed | 2024-04-13T16:08:31Z |
| format | Article |
| id | doaj.art-e83dd58372be43cfabe209ba4085b937 |
| institution | Directory Open Access Journal |
| issn | 2589-5559 |
| language | English |
| last_indexed | 2024-04-13T16:08:31Z |
| publishDate | 2019-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj.art-e83dd58372be43cfabe209ba4085b9372022-12-22T02:40:20ZengElsevierJHEP Reports2589-55592019-08-0112120130The oncogenic role of hepatitis delta virus in hepatocellular carcinomaMarc Puigvehí0Carlos Moctezuma-Velázquez1Augusto Villanueva2Josep M. Llovet3Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Hepatology Section, Gastroenterology Department, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Catalonia, SpainMount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAMount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Denotes co-senior authorship.; Corresponding authors. Addresses: Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Box 11-23, New York, NY 10029, USA; Tel.: +1 2126599503, fax: +1 212 849 2574, (JM. Llovet); or Division of Liver Diseases, Division of Hematology and Medical Oncology, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA (A. Villanueva).Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain; Denotes co-senior authorship.; Corresponding authors. Addresses: Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, Box 11-23, New York, NY 10029, USA; Tel.: +1 2126599503, fax: +1 212 849 2574, (JM. Llovet); or Division of Liver Diseases, Division of Hematology and Medical Oncology, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029 USA (A. Villanueva).Summary: Hepatitis delta virus (HDV) is a small defective virus that needs hepatitis B virus (HBV) to replicate and propagate. HDV infection affects 20-40 million people worldwide and pegylated interferon (PegIFN) is the only recommended therapy. There is limited data on the contribution of HDV infection to HBV-related liver disease or liver cancer. Evidence from retrospective and cohort studies suggests that HBV/HDV coinfection accelerates progression to cirrhosis and is associated with an increased risk of hepatocellular carcinoma (HCC) development compared to HBV monoinfection. Although the life cycle of HDV is relatively well known, there is only ancillary information on the molecular mechanisms that can drive specific HDV-related oncogenesis. No thorough reports on the specific landscape of mutations or molecular classes of HDV-related HCC have been published. This information could be critical to better understand the uniqueness, if any, of HDV-related HCC and help identify novel targetable mutations. Herein, we review the evidence supporting an oncogenic role of HDV, the main reported mechanisms of HDV involvement and their impact on HCC development. Keywords: Hepatitis B virus, liver cancer, HCC, co-infection, molecular pathogenesis, defective, superinfectionhttp://www.sciencedirect.com/science/article/pii/S2589555919300345 |
| spellingShingle | Marc Puigvehí Carlos Moctezuma-Velázquez Augusto Villanueva Josep M. Llovet The oncogenic role of hepatitis delta virus in hepatocellular carcinoma JHEP Reports |
| title | The oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| title_full | The oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| title_fullStr | The oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| title_full_unstemmed | The oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| title_short | The oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| title_sort | oncogenic role of hepatitis delta virus in hepatocellular carcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2589555919300345 |
| work_keys_str_mv | AT marcpuigvehi theoncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT carlosmoctezumavelazquez theoncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT augustovillanueva theoncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT josepmllovet theoncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT marcpuigvehi oncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT carlosmoctezumavelazquez oncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT augustovillanueva oncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma AT josepmllovet oncogenicroleofhepatitisdeltavirusinhepatocellularcarcinoma |